**Supplementary materials**

**Literature search**

Searches wereconducted between 4th December 2018 and 5th April 2019, using the sources listed below. The search was restricted to studies published from the 1st January 2009 onwards.

* Medline
* Embase
* CINAHL
* PsychINFO
* Cochrane Database of Systematic Reviews
* Cochrane Central Register of Controlled Trials
* DARE
* HTA database
* Current Controlled Trials
* Prospero database

The following shows the final search strategy used to search Medline. The strategy was adapted to search the other databases. All search strategies are available on request.

|  |
| --- |
| **Medline** |
| **ATMP Stem** |
| 1 | exp "Cell- and Tissue-Based Therapy"/ |
| 2 | exp Genetic Therapy/ |
| 3 | Regenerative Medicine/ |
| 4 | Tissue Engineering/ |
| 5 | exp Gene Transfer Techniques/ |
| 6 | exp stem cells/ |
| 7 | exp Multipotent Stem Cells/ |
| 8 | Induced Pluripotent Stem Cells/ |
| 9 | exp Stromal Cells/ |
| 10 | stem cell research/ |
| 11 | (advanced therapy medicinal product$ or advanced therapy medicinal product$ or atmp$).tw. |
| 12 | regenerative medicine$.tw. |
| 13 | advanced therap$.tw. |
| 14 | (gene-therapy medicinal product$ or gene therapy medicinal product$ or gtmp$).tw. |
| 15 | (cell-therapy medicinal product$ or cell therapy medicinal product$ or ctmp$).tw. |
| 16 | (tissue engineered product$ or tissue-engineered product$ or tep or teps).tw. |
| 17 | (regenerative medicine advanced therap$ or rmat$).tw. |
| 18 | "human cells, tissues, and cellular and tissue-based products (HCT/Ps)".tw. |
| 19 | "human cells, tissues, and cellular and tissue-based product (HCT/P)".tw. |
| 20 | regenerative therap$.tw. |
| 21 | ("cell and gene therapy product" or "cell and gene therapy products" or cgtp or cgtps).tw. |
| 22 | or/1-21 |
| 23 | (Tisagenlecleucel or Kymriah or cart 19 or cart19 or "ctl 019" or ctl019).tw. |
| 24 | (Axicabtagene ciloleucel or Yescarta or kte c19 or ktec19).tw. |
| 25 | (Voretigene neparvovec-rzyl or Voretigene neparvovec?rzyl or Luxturna).tw. |
| 26 | (Talimogene laherparepvec or Imlygic or oncovex or t vec).tw. |
| 27 | (Strimvelis or gsk 2696273 or gsk2696273).tw. |
| 28 | Holoclar.tw. |
| 29 | MACI.tw. |
| 30 | (Provenge or sipuleucel t or apc 8015 or apc8015).tw. |
| 31 | (Glybera or alipogene tiparvovec or "amt 011" or amt011 or aav1 lpls447x).tw. |
| 32 | Zalmoxis.tw. |
| 33 | Spherox.tw. |
| 34 | or/23-33 |
| 35 | 22 or 34 |
| **Patient Filter (adapted SIGN Patient Issues filter)** |
| 36 | ((patient$ or consumer$ or public) adj2 (decisi$ or decid$)).ti,ab. |
| 37 | "Patient Acceptance of Health Care"/ |
| 38 | exp attitude to health/ |
| 39 | Patient Preference/ |
| 40 | "patient satisfaction".ti. |
| 41 | exp health education/ |
| 42 | patient education as topic/ |
| 43 | health knowledge, attitudes, practice/ |
| 44 | "informed choice".ti,ab. |
| 45 | "shared decision making".ti,ab. |
| 46 | ("focus group" adj3 (patient$ or parent$ or famil$ or spouse$ or public)).ti,ab. |
| 47 | Consumer Advocacy/ |
| 48 | patient advocacy/ |
| 49 | exp professional-patient relations/ |
| 50 | ((patient$ or consumer$ or parent$ or famil$ or spouse$ or carer$ or public) adj (attitude$ or involvement or desir$ or perspective$ or activation or view$ or preference$ or experience$ or knowledge$ or understand$ or awareness$)).ti,ab. |
| 51 | exp decision making/ |
| 52 | exp communication/ |
| 53 | vignette\*.ti,ab. |
| 54 | "focus group$".ti,ab. |
| 55 | focus groups/ |
| 56 | exp empirical research/ |
| 57 | narration/ |
| 58 | (meta-ethnography or metaethnography).ti,ab. |
| 59 | grounded theor\*.ti,ab. |
| 60 | hermeneutic.ti,ab. |
| 61 | (inductive adj2 (analys\* or grounded or reasoning)).ti,ab. |
| 62 | (ethnograph\* or ethnological or ethnomethodol\* or ethnonursing research).ti,ab. |
| 63 | qualitative.ti. |
| 64 | exp qualitative research/ |
| 65 | (qualitative adj (research or stud\* or data)).ab. |
| 66 | exp Community Participation/ |
| 67 | Public Opinion/ |
| 68 | or/36-67 |
| 69 | 35 and 68 |
| 70 | limit 69 to yr="2009 -Current" |

**Supplementary Figure 1 PRISMA diagram showing literature search and selection process [1]**

Additional records identified through other sources
(n =0 )

Records identified through database searching
(n = 11,786)

Records after duplicates removed
(n = 10,735)

Records screened
(n = 10,735)

Records excluded
(n =10,584 )

Studies included in qualitative synthesis
(n = 33)

Additional studies identified through citation searching and also included qualitative synthesis (n = 2)

Full-text articles assessed for eligibility
(n = 151)

Full-text articles excluded, with reasons
(n =118 )

**Supplementary Table 1: Included studies**

**Full data extraction tables for the included studies are available from the authors on request.**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Author** | **Type of therapy** | **Participants** | **Indication** | **Country** | **Time of data collection** | **Design/method** | **Reference** |
| Aked et al. (2017)  | Cell | Patients | Ischaemic stroke | Sweden | Between 2014 and 2017 | Quantitative questionnaire | [2] |
| Allum et al. (2017) | Cell | Public | General | Europe; USA; Canada | 2005 | Quantitative questionnaire | [3] |
| Benjaminy et al. (2014) | Gene  | Patients; clinicians; patient advocates | Choroideremia | Canada | June 2011 to June 2012 | Semi-structured interviews | [4] |
| Blendon et al. (2016) | Gene  | Public | General | US | 1986 to 2016 | Analysis of public opinion polls | [5] |
| Bubela et al. (2012) | Cell | Media (newspaper articles) | General | Canada | 1990 to 2010 | Word frequency analysis | [6] |
| Chung et al. (2014) | Cell | Patients; carers | Parkinson's disease | Korea | April 2013 to June 2013 | Questionnaire | [7] |
| Clover et al. (2012) | Cell/tissue engineering | Patients | Burns | Ireland | 2010 | Quantitative questionnaire | [8] |
| Cunningham et al. (2018) | Cell | Patients; carers | Stroke | UK | June to October 2016 | Focus group (conversation café) | [9] |
| Dasgupta et al. (2014) | Cell | Public | General | USA | 2014 or earlier | Focus group | [10] |
| Eijkholt et al. (2012) | Cell | Friends and family; patients | Spinal cord injury | Canada | June 2009 to February 2010 | Focus groups and interviews | [11] |
| Einsiedel et al. (2009) | Cell | Patients; public; caregivers | General | Canada | 2009 or earlier - not specified | Focus groups | [12] |
| Evans and Kelley (2011) | Cell | Public | General | USA | 2009 | Quantitative questionnaire | [13] |
| Hodges et al. (2012) | Cell | Patients (pregnant women) | General and 15 specific disorders | Australia | 2009/2010 | Quantitative questionnaire | [14] |
| Horch et al. (2016) | Cell | Public (firefighters) | Burns | Canada | 2016 or earlier | Mixed methods; quantitative online survey followed by a qualitative semi-structured interview | [15] |
| Hudson and Orviska (2011) | Gene  | Public | General | Europe | 2005 | Eurobarometer public opinion survey | [16] |
| Jacob et al. (2015) | Cell | Patients | Spinal cord injury | Canada; USA | 2015 or earlier | Qualitative interviews | [17] |
| Jannetta et al. (2010) | Gene  | Patients | Cystic fibrosis | UK | 2009 or earlier - not specified | Qualitative interviews | [18] |
| Kim et al. (2013) | Cell | Patients | Ischaemic stroke | South Korea | Jan to May 2011 | Quantitative and qualitative interviews | [19] |
| King et al. (2010) | Cell | Patient; Public | HIV/AIDs | USA | 2010 or earlier | Focus groups | [20] |
| King and Lyall (2018) | Cell | Public | Blood transfusion | Scotland | 2011 to 2017 | Ethnographic study; 15 interviews and 12 focus groups | [21] |
| Nelissen et al. (2016) | Cell | Patients; public | Cancer | Belgium | 2016 or earlier | Cross sectional survey | [22] |
| Nelles et al. (2015) | Gene  | Patients | Genetic eye disease | Germany | 2015 or earlier | Quantitative questionnaires and qualitative interviews | [23] |
| Nisbet et al. (2014) | Cell | Public | General | USA | 2002 to 2010 | Quantitative surveys | [24] |
| Peay et al. (2018) | Gene  | Patients; carers | Duchenne Muscular Dystrophy | USA | March to May 2017 | Qualitative interviews | [25] |
| Rachul and Caulfield (2015) | Cell | Public | General | USA; Canada | Earlier than February 2015 | Qualitative analysis of news media articles and readers' comments | [26] |
| Robillard et al. (2013) | Gene  | Public | General | Canada | 2006-2010 | Content analysis | [27] |
| Robillard et al. (2014) | Gene  | Public | General | USA; Canada | 2014 or earlier | Online survey | [28] |
| Shineha et al. (2018) | Cell | Public; scientists | General | Japan | October 2015 to March 2016 | Quantitative questionnaire | [29] |
| Sipp D. (2017) | Cell | Public | General | USA | 2016 | Content analysis | [30] |
| Stewart et al. (2015) | Cell | Public | General | UK | Aug to Sep 2014 | Qualitative interviews and questionnaire | [31] |
| Strong H et al. (2017) | Gene  | Patients | Sickle cell | USA | 2010-2012 | Focus groups | [32] |
| Tanner et al. (2017) | Cell | Patients; carers; clinicians; patient advocates | General | Australia | 2012-2014 | Qualitative interviews | [33] |
| Vicsek and Gergely (2011) | Cell | Media newspaper articles; public | General | Hungary | 2006 to 2008 | Qualitative content analysis and focus groups | [34] |
| Wang et al. (2017) | Gene  | Public; clinicians | General | China | August 2016 to November 2016 | Online survey | [35] |
| Wright et al. (2016) | Cell | Patients | Post-obstetric incontinence | UK | 2016 or earlier | Quantitative questionnaire with some free text response options | [36] |

**References**

1. Liberati A, Altman DG, Tetzlaff J *et al*. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration*.* *BMJ* 339 b2700 (2009).
2. Aked J, Delavaran H, Lindvall O, Norrving B, Kokaia Z, Lindgren A. Attitudes to stem cell therapy among ischemic stroke survivors in the lund stroke recovery study*.* *Stem Cells Dev.* 26(8), 566-572 (2017).
3. Allum N, Allansdottir A, Gaskell G *et al*. Religion and the public ethics of stem-cell research: attitudes in Europe, Canada and the United States*.* *PLoS ONE* 12(4), e0176274 (2017).
4. Benjaminy S, Macdonald I, Bubela T. "Is a cure in my sight?" Multi-stakeholder perspectives on phase I choroideremia gene transfer clinical trials*.* *Genet. Med.* 16(5), 379-385 (2014).
5. Blendon RJ, Gorski MT, Benson JM. The public and the gene-editing revolution*.* *N. Engl. J. Med.* 374(15), 1406-1411 (2016).
6. Bubela T, Li MD, Hafez M, Bieber M, Atkins H. Is belief larger than fact: expectations, optimism and reality for translational stem cell research*.* *BMC Med.* 10 133 (2012).
7. Chung SJ, Koh SB, Ju Y-S, Kim JW. Nationwide survey of patient knowledge and attitudes towards human experimentation using stem cells or bee venom acupuncture for Parkinson’s disease*.* *JMD* 7(2), 84-91 (2014).
8. Clover AJ, O'Neill BL, Kumar AH. Analysis of attitudes toward the source of progenitor cells in tissue-engineered products for use in burns compared with other disease states*.* *Wound Repair Regen.* 20(3), 311-316 (2012).
9. Cunningham NA, Abhyankar P, Cowie J, Galinsky J, Methven K. Regenerative medicine: stroke survivor and carer views and motivations towards a proposed stem cell clinical trial using placebo neurosurgery*.* *Health Expect.* 21(1), 367-378 (2018).
10. Dasgupta I, Bollinger J, Mathews DJ, Neumann NM, Rattani A, Sugarman J. Patients' attitudes toward the donation of biological materials for the derivation of induced pluripotent stem cells*.* *Cell Stem Cell* 14(1), 9-12 (2014).
11. Eijkholt M, Kwon BK, Mizgalewicz A, Illes J. Decision-making in stem cell trials for spinal cord injury: the role of networks and peers*.* *Regen. Med.* 7(4), 513-522 (2012).
12. Einsiedel E, Premji S, Geransar R, Orton NC, Thavaratnam T, Bennett LK. Diversity in public views toward stem cell sources and policies*.* *Stem Cell Rev.* 5(2), 102-107 (2009).
13. Evans MD, Kelley J. US attitudes toward human embryonic stem cell research*.* *Nat. Biotechnol.* 29(6), 484-488 (2011).
14. Hodges RJ, Bardien N, Wallace E. Acceptability of stem cell therapy by pregnant women*.* *Birth (Berkeley, Calif.)* 39(2), 91-97 (2012).
15. Horch JD, Carr ECJ, Harasym P, Burnett L, Biernaskie J, Gabriel V. Firefighter willingness to participate in a stem cell clinical trial for burns: a mixed methods study*.* *Burns* 42(8), 1740-1750 (2016).
16. Hudson J, Orviska M. European attitudes to gene therapy and pharmacogenetics*.* *Drug Discov. Today* 16(19-20), 843-847 (2011).
17. Jacob KJ, Kwon BK, Lo C, Snyder J, Illes J. Perspectives on strategies and challenges in the conversation about stem cells for spinal cord injury*.* *Spinal Cord* 53(11), 811-815 (2015).
18. Jannetta EE, Cochrane SC, Morris PG, Dewar MH, Innes JA. A qualitative study of cystic fibrosis (CF) patients' expectations of gene therapy*.* *J. Cyst. Fibros.* 1) S101 (2010).
19. Kim YS, Chung DI, Choi H *et al*. Fantasies about stem cell therapy in chronic ischemic stroke patients*.* *Stem Cells Dev.* 22(1), 31-36 (2013).
20. King WD, Wyatt GE, Liu H, Williams JK, Dinardo AD, Mitsuyasu RT. Pilot assessment of HIV gene therapy-hematopoietic stem cell clinical trial acceptability among minority patients and their advisors*.* *J. Natl. Med. Assoc.* 102(12), 1123-1128 (2010).
21. King E, Lyall C. What's in a name: are cultured red blood cells 'natural'? *Sociol. Health Illn.* 40(4), 687-701 (2018).
22. Nelissen S, Van Den Bulck J, Lemal M, Beullens K. Stem cell research: the role of information seeking and scanning*.* *Health Info. Libr. J* 33(4), 269-282 (2016).
23. Nelles M, Stieger K, Preising MN, Kruse J, Lorenz B. Shared decision-making, control preferences and psychological well-being in patients with RPE65 deficiency awaiting experimental gene therapy*.* *Ophthalmic Res.* 54(2), 96-102 (2015).
24. Nisbet MC, Becker AB. Public opinion about stem cell research, 2002 to 2010*.* *Public Opin. Q.* 78(4), 1003-1022 (2014).
25. Peay H, Fischer R, Beaverson K *et al*. Parent and adult patient attitudes about gene therapy as a therapeutic option for duchenne muscular dystrophy*.* *Value Health* 21(Supplement 1), S256 (2018).
26. Rachul C, Caulfield T. Gordie Howe's Stem Cell 'Miracle': A qualitative analysis of news coverage and readers' comments in newspapers and sports websites*.* *Stem Cell Rev. Rep.* 11(5), 667-675 (2015).
27. Robillard JM, Whiteley L, Johnson TW, Lim J, Wasserman WW, Illes J. Utilizing social media to study information-seeking and ethical issues in gene therapy*.* *J. Med. Internet Res.* 15(3), e44 (2013).
28. Robillard JM, Roskams-Edris D, Kuzeljevic B, Illes J. Prevailing public perceptions of the ethics of gene therapy*.* *Hum. Gene Ther.* 25(8), 740-746 (2014).
29. Shineha R, Inoue Y, Ikka T, Kishimoto A, Yashiro Y. A comparative analysis of attitudes on communication toward stem cell research and regenerative medicine between the public and the scientific community*.* *Stem Cells Transl. Med.* 7(2), 251-257 (2018).
30. Sipp D. Identity and ownership issues in the regulation of autologous cells*.* *Regen. Med.* 12(7), 827-838 (2017).
31. Stewart CJ, Miller C, Mcpherson C *et al*. Patient's attitude towards the donation and use of adipose tissue and adipose derived stem cells for research*.* *Journal Plast. Reconstr. Aesthet. Surg.* 68(4), 588-589 (2015).
32. Strong H, Mitchell M, Goldstein-Leever A *et al*. Patient perspectives on gene transfer therapy for sickle cell disease. [Erratum appears in Adv Ther. 2017 Aug 2;:; PMID: 28770518]*.* *Adv. Ther.* 34(8), 2007-2021 (2017).
33. Tanner C, Petersen A, Munsie M. 'No one here's helping me, what do you do?': Addressing patient need for support and advice about stem cell treatments*.* *Regen. Med.* 12(7), 791-801 (2017).
34. Vicsek L, Gergely J. Media presentation and public understanding of stem cells and stem cell research in Hungary*.* *New Genet. Soc.* 30(1), 1-26 (2011).
35. Wang JH, Wang R, Lee JH *et al*. Public attitudes toward gene therapy in China*.* *Mol. Ther. Methods Clin. Dev.* 6 40-42 (2017).
36. Wright B, Emmanuel A, Athanasakos E *et al*. Women's views on autologous cell-based therapy for post-obstetric incontinence*.* *Regen. Med.* 11(2), 169-180 (2016).